SEARCH

SEARCH BY CITATION

Keywords:

  • dogs;
  • hydromorphone;
  • maropitant;
  • vomiting

Abstract

Objective  The goal of this study was to evaluate the effectiveness of maropitant (Cerenia®) in preventing vomiting after premedication with hydromorphone.

Study design  Randomized, blinded, prospective clinical study.

Animals  Eighteen dogs ASA I/II admitted for elective orthopedic surgical procedures. The dogs were a mixed population of males and females, purebreds and mixed breeds, 1.0–10.2 years of age, weighing 3–49.5 kg.

Methods  Dogs were admitted to the study if they were greater than 1 year of age, healthy and scheduled to undergo elective orthopedic surgery. Dogs were randomly selected to receive one of two treatments administered by subcutaneous injection. Group M received 1.0 mg kg−1 of maropitant, Group S received 0.1 mL kg−1 of saline 1 hour prior to anesthesia premedication. Dogs were premedicated with 0.1 mg kg−1 of hydromorphone intramuscularly. A blinded observer documented the presence of vomiting, retching and/or signs of nausea for 30 minutes after premedication.

Results  All dogs in S vomited (6/9), retched (1/9) or displayed signs of nausea (2/9). None (0/9) of the dogs in M vomited, retched or displayed signs of nausea. Dogs in M had significantly fewer incidences of vomiting (p = 0.0090), vomiting and retching (p = 0.0023) and vomiting, retching and nausea (p < 0.0001) when compared to S.

Conclusion and clinical relevance  Maropitant prevents vomiting, retching and nausea associated with intramuscular hydromorphone administration in dogs.